U.S. And Europe Pharmaceutical Manufacturing Market Size, Share & Trends Analysis Report By Product Type, By Type, By Drug Development Type, By Formulation, By Routes of Administration, And Segment - Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The U.S. and Europe pharmaceutical manufacturing market size was exhibited at USD 378.9 billion in 2022 and is projected to hit around USD 738.42 billion by 2032, growing at a CAGR of 6.9% during the forecast period 2023 to 2032.

Key Pointers:

• The small molecule segment held the largest share in 2022 and is anticipated to grow at a lucrative rate during the projected period
• The small molecule segment held the largest share of the market in 2022, owing to the high consumption rate of small molecules and increasing product approvals
• The outsource segment accounted for the largest market share in 2022 due to various benefits associated with outsource manufacturing such as low investment and high manufacturing efficiency
• Based on formulation, the tablets dominated the U.S. & Europe pharmaceutical manufacturing industry in 2022, whereas the sprays segment is anticipated to be the fastest-growing segment
• The oral segment was the largest in 2022 owing to the high availability of top-selling preparations as an oral dosage form and a high demand for oral formulations
• Based on the therapy area, the cancer segment held the largest revenue share of the market. Whereas the respiratory diseases segment is anticipated to grow at an exponential growth rate
• Europe is expected to exhibit the fastest growth during the forecast period due to favorable government policies and ongoing research activities

Report Scope of the U.S. and Europe pharmaceutical manufacturing Market

The introduction of novel technologies, adoption of more efficient & cost-effective manufacturing processes, increasing investment by key pharmaceutical manufactures, and a large number of pharmaceutical manufacturing plants in the region are expected to increase the market growth. Moreover, the shift in paradigm toward data-rich, smart, paperless, integrated operations, and increasing penetration of automation & artificial intelligence has led to precise & efficient manufacturing. Such ongoing developments and progress have transformed the U.S. & Europe pharmaceutical manufacturing industry.

The presence of supportive regulatory legislation, patentability norms, high investments in the pharmaceutical industry, and increasing healthcare expenditure remain key drivers of growth. In addition, the rising trend of third-party production across the pharmaceutical sector along with the increased emphasis on cost-cutting approaches are likely to provide lucrative growth opportunities.

A continuous increase in the number of clinical trials of pharmaceutical products is expected to create numerous opportunities for market growth in the coming years. According to ClinicalTrials.gov, as of January 2023, a total of 137,145 ongoing clinical studies were registered in the U.S., which accounts for 31% of overall clinical trials. This increase in the number of clinical studies indicates the growth of the pharmaceutical industry, which is likely to create new avenues for market stakeholders.

Moreover, the majority of pharmaceutical manufacturers have shifted their preference toward continuous production approaches to overcome medicines shortages, reduces production cost, and improve manufacturing efficiencies. For instance, in January 2021, CONTINUUS Pharmaceuticals Inc. announced a receipt of USD 69.3 million U.S. government contract to speed up country-level production of three essential medicines to treat severely ill patients. Moreover, this contract helped the company to enable cost-efficient production to facilitate the delivery of high-quality and affordable therapeutics to patients.

Government initiatives to establish domestic pharmaceutical manufacturing sites are one of the determinants of pharmaceutical manufacturing market growth. For instance, in April 2022, CureVac and GSK plc entered into a partnership to be part of the German Pandemic contingency plan to increase mRNA production capacity and the government will receive access to CureVac’s production capacity until 2029.

The UK government is taking action to establish local manufacturing through Medicines Manufacturing Innovation Centre. Under this program, drug makers, academic institutions, healthcare providers, and regulatory bodies are expected to combine their resources at the facility to test and enhance new technologies, including autonomous production.

Furthermore, the organic and inorganic developments undertaken by pharmaceutical companies to strengthen their business avenues are anticipated to support market expansion. For instance, in October 2021, Samsung Biologics and Enzolytics, Inc. signed a development & manufacturing agreement for Anti-SARS-CoV-2 Monoclonal Antibody and Anti-HIV therapies. Similarly, in February 2021, WuXi STA purchased Bristol Myers Squibb’s manufacturing unit in Switzerland. This expansion will further enhance its existing capabilities.

Some of the prominent players in the U.S. and Europe pharmaceutical manufacturing Market include:

• AbbVie Inc
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Merck & Co., Inc
• Johnson & Johnson Services, Inc
• GSK plc
• Sanofi
• Lonza
• Samsung Biologics
• Lily
• Pfizer,Inc

Segments Covered in the Report

This report forecasts the volume and revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor has segmented the U.S. and Europe pharmaceutical manufacturing market.

By Product Type 

• Large Molecule
  • Monoclonal Antibodies
  • Vaccines
  • Cell & Gene Therapy
  • Others
• Small Molecule

By Drug Development Type 

• Outsource
• In-house

By Formulation 

• Tablets
• Capsules
• Injectables
• Sprays
• Suspensions
• Powders
• Others

By Route of Administration 

• Oral
• Topical
• Parenterals
• Inhalations
• Others

By Therapy Area 

• Cardiovascular Diseases
• Pain
• Diabetes
• Cancer
• Respiratory Diseases
• Others

By Prescription Requirements 

• Prescription Medicines
• Over-the-counter (OTC) Medicines

By Age Type 

• Children & Adolescents
• Adults
• Geriatric

By Sales Channel 

• Retail
• Non-retail

By Regional 

• U.S.
• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway